Designing functional in vivo biosensors for real-time monitoring of glucose remains a challenge due to the inflammatory response and fibrous capsule that forms around the sensor, diminishing analytical performance. Biosensors capable of more accurate glucose monitoring immediately after implantation and over extended periods (weeks instead of days) would greatly enhance the utility of such devices for diabetes management. Based on an amazing postdoctoral research experience with Prof. Meyerhoff, I was able to initiate a research program focused on the design of sensor membranes that release nitric oxide, a mediator of the foreign body response (FBR) and wound healing promotor. Through NIH-sponsored research, we have been able to determine specific NO fluxes and durations that are useful for mitigating implant associated FBR and improving the in vivo analytical performance of such sensors. Through this research, we have established new chemistries for storing and releasing therapeutic levels of nitric oxide. Based on nitric oxide’s role as a potent antimicrobial agent, our work has evolved to include the development and study of nitric oxide-based therapeutics for diseases exacerbated by bacterial infections, including bronchiectasis and periodontitis. My talk will provide an overview of our research activities in these areas with special acknowledgement to how very little of what we are working on today would have been possible without the unrivalled mentorship and enthusiasm of Mark Meyerhoff.